Merck & Co’s clesrovimab could become the third antibody approved for the prevention of respiratory syncytial virus (RSV) in infants following pivotal data indicating its effectiveness. But at first sight, it seems not to have attained quite the same level of efficacy as Sanofi and AstraZeneca’s approved product, Beyfortus, potentially limiting its appeal.
Merck & Co’s Clesrovimab Has Beyfortus Hill To Climb In RSV
Full data from Merck & Co’s Phase IIb/III trial of its novel RSV antibody suggest that it will have to fight hard against Sanofi/AstraZeneca’s leader.
More from Clinical Trials
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
More from Therapy Areas
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.